cilostazol has been researched along with Atrial Fibrillation in 7 studies
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 9.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol." | 7.71 | [Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001) |
| " We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes." | 7.70 | Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000) |
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 5.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF)." | 5.19 | Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. ( Açar, G; Akçakoyun, M; Alizade, E; Avcı, A; Bulut, M; Esen, AM; Güler, A; Kalkan, ME; Pala, S; Sahin, M; Simşek, Z, 2014) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol." | 3.71 | [Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001) |
| " We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes." | 3.70 | Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 2 |
| Nomura, K | 1 |
| Abe, K | 1 |
| Uno, M | 1 |
| Okada, Y | 1 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 1 |
| Kimura, K | 1 |
| Apostolakis, S | 1 |
| Lip, GY | 1 |
| Shantsila, E | 1 |
| Alizade, E | 1 |
| Sahin, M | 1 |
| Simşek, Z | 1 |
| Açar, G | 1 |
| Bulut, M | 1 |
| Güler, A | 1 |
| Avcı, A | 1 |
| Kalkan, ME | 1 |
| Pala, S | 1 |
| Akçakoyun, M | 1 |
| Esen, AM | 1 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Nagata, I | 1 |
| Atarashi, H | 1 |
| Endoh, Y | 1 |
| Saitoh, H | 1 |
| Kishida, H | 1 |
| Hayakawa, H | 1 |
| Toyonaga, S | 1 |
| Nakatsu, T | 1 |
| Murakami, T | 1 |
| Kusachi, S | 1 |
| Mashima, K | 1 |
| Tominaga, Y | 1 |
| Yamane, S | 1 |
| Uesugi, T | 1 |
| Kanai, H | 1 |
| Tsuji, T | 1 |
| Kishida, M | 1 |
| Watanabe, K | 1 |
| Tsuruoka, T | 1 |
1 review available for cilostazol and Atrial Fibrillation
| Article | Year |
|---|---|
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
3 trials available for cilostazol and Atrial Fibrillation
| Article | Year |
|---|---|
Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke.
Topics: Aged; Atrial Fibrillation; Cilostazol; Humans; Male; Prospective Studies; Retrospective Studies; Ris | 2020 |
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
Topics: Aged; Atrial Fibrillation; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periphe | 2014 |
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Topics: Administration, Oral; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardi | 1998 |
3 other studies available for cilostazol and Atrial Fibrillation
| Article | Year |
|---|---|
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Natriuretic Factor; Bradycardia; Cilostazol; Ci | 2000 |
[Effects of cilostazol in patients with bradycardiac atrial fibrillation].
Topics: Aged; Atrial Fibrillation; Atrial Natriuretic Factor; Blood Pressure; Bradycardia; Cilostazol; Drug | 2001 |